相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1952
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers at The Lundquist Institute have developed VX-01, a humanized monoclonal antibody that effectively targets the CotH protein on fungal cells causing mucormycosis, a deadly infection with mortality rates approaching 60%. - The novel antibody prevents fungal invasion of blood vessels, allowing antifungal medications to reach infected tissues more effectively, potentially eliminating the need for disfiguring surgeries currently required to treat the infection. - Mucormycosis cases have steadily increased over four decades, with approximately 4,000 annual cases in the US and 200,000 in Southeast Asia, particularly affecting immunocompromised patients and those with diabetes.
- Type 1 diabetes, traditionally associated with lean individuals, is now frequently complicated by obesity, leading to increased cardiovascular risks and necessitating new treatment approaches. - Current projections indicate 50% of U.S. adults will be obese by 2030, prompting experts to recommend early cardiovascular screening and preventive strategies for T1D patients. - GLP-1 receptor agonists show promise in addressing both weight management and cardiovascular risk reduction in T1D patients, potentially transforming traditional insulin-focused treatment paradigms.
